Interestingly, aerobic glycolysis, known to take place mostly in astrocytes, was observed to decline as tau accumulated in preclinical AD individuals [129], supporting astrocyte dysfunction as an early event in AD. The gene discussed is MAPT; the disease is Alzheimer disease.